Remimazolam
- Generic Name
- Remimazolam
- Brand Names
- Byfavo
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19BrN4O2
- CAS Number
- 308242-62-8
- Unique Ingredient Identifier
- 7V4A8U16MB
- Background
Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotran...
- Indication
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
- Associated Conditions
- Procedural Sedation
- Associated Therapies
- -
Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective Surgery
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 469
- Registration Number
- NCT03661489
- Locations
- 🇩🇪
University of Erlangen, Erlangen, Bavaria, Germany
A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03329014
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT02532647
- Locations
- 🇺🇸
Jupiter Medical Center, Jupiter, Florida, United States
🇺🇸Indiana University Division of Gastroenterology/Hepatology, Indianapolis, Indiana, United States
🇺🇸Delta Research Partners Inc, Monroe, Louisiana, United States
Study of the Efficacy and Safety of Remimazolam in General Anesthesia in Adults Undergoing Cardiac Surgery
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02523859
- Locations
- 🇩🇪
Herzzentrum Leipzig GmbH, Leipzig, Germany
A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 446
- Registration Number
- NCT02296892
- Locations
- 🇺🇸
Washington University School of Medicine/Barnes-Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸Sun City Office, Sun City Center, Florida, United States
🇺🇸Pab Clinical Research, Brandon, Florida, United States
A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 461
- Registration Number
- NCT02290873
- Locations
- 🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸Borland-Grover Clinic, P.A, Jacksonville, Florida, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
Remimazolam Phase II Cardiac Anesthesia Study
- Conditions
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT01937767
- Locations
- 🇩🇪
Herzzentrum Leipzig GmbH, Leipzig, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.